Search research articles
Contact Us
Filters
Showing results (71-80 of 82) with videos related to
Page
of 9
Sort By:
Blood Advances
|
January 7, 2026
Spectrum, prevalence, and clinical correlates of PPM1D mutations in patients with clonal hematopoiesis and clonal cytopenias
Talha Badar, Ludovica Marando, Eric Latorre-Crespo, et al.
Blood Cancer Journal
|
August 14, 2025
Clinical and molecular characterization of TP53-mutant acute lymphoblastic leukemia in adults
Ethan J Harris, Diren Arda Karaoglu, Madina Sukhanova, et al.
Transplantation and Cellular Therapy
|
February 12, 2023
Multicenter Long-Term Follow-Up of Allogeneic Hematopoietic Cell Transplantation with Omidubicel: A Pooled Analysis of Five Prospective Clinical Trials
Chenyu Lin, Aurelie Schwarzbach, Jaime Sanz, et al.
Blood
|
May 19, 2026
Consensus Recommendations for CAR T-Cell Administration in Adult Acute Lymphoblastic Leukemia: a Modified Delphi Study
Lori Muffly, Noelle V Frey, Gregory W Roloff, et al.
Transplantation and Cellular Therapy
|
June 27, 2026
Allogeneic Hematopoietic Cell Transplant Following Standard of Care Brexucabtagene Autoleucel (Brexu-cel) in Adults with B-Cell Acute Lymphoblastic Leukemia (B-ALL): Results from the Real-World Outcomes Collaborative of CAR T in Adult ALL (ROCCA)
Rawan G Faramand, Amy Zhang, Gregory W Roloff, et al.
Blood Advances
|
June 25, 2026
Improved Outcomes with TKI Maintenance Following Brexucabtagene Autoleucel in Philadelphia-chromosome ALL
Tamer Othman, Gregory W Roloff, Katharine Miller, et al.
Blood Cancer Journal
|
May 9, 2025
Outcomes of elderly patients with relapsed refractory multiple myeloma (RRMM) treated with teclistamab: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium
Oren Pasvolsky, Danai Dima, Lei Feng, et al.
Blood Advances
|
October 6, 2025
CAR HEMATOTOX independently predicts outcomes after CD19 CAR-T therapy for acute lymphoblastic leukemia
Yannis K Valtis, Chenyu Lin, David Nemirovsky, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 17, 2024
Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALL
Gregory W Roloff, Ibrahim Aldoss, Noam E Kopmar, et al.
Blood Advances
|
August 2, 2024
Impact of prior inotuzumab ozogamicin treatment on brexucabtagene autoleucel outcomes in adults with B-cell ALL
Ibrahim Aldoss, Gregory W Roloff, Rawan Faramand, et al.
Page
of 9
Search research articles
Search
Showing results (71-80 of 82) with videos related to
Sort By:
Page
of 9
Blood Advances
|
January 7, 2026
Spectrum, prevalence, and clinical correlates of PPM1D mutations in patients with clonal hematopoiesis and clonal cytopenias
Talha Badar, Ludovica Marando, Eric Latorre-Crespo, et al.
Blood Cancer Journal
|
August 14, 2025
Clinical and molecular characterization of TP53-mutant acute lymphoblastic leukemia in adults
Ethan J Harris, Diren Arda Karaoglu, Madina Sukhanova, et al.
Transplantation and Cellular Therapy
|
February 12, 2023
Multicenter Long-Term Follow-Up of Allogeneic Hematopoietic Cell Transplantation with Omidubicel: A Pooled Analysis of Five Prospective Clinical Trials
Chenyu Lin, Aurelie Schwarzbach, Jaime Sanz, et al.
Blood
|
May 19, 2026
Consensus Recommendations for CAR T-Cell Administration in Adult Acute Lymphoblastic Leukemia: a Modified Delphi Study
Lori Muffly, Noelle V Frey, Gregory W Roloff, et al.
Transplantation and Cellular Therapy
|
June 27, 2026
Allogeneic Hematopoietic Cell Transplant Following Standard of Care Brexucabtagene Autoleucel (Brexu-cel) in Adults with B-Cell Acute Lymphoblastic Leukemia (B-ALL): Results from the Real-World Outcomes Collaborative of CAR T in Adult ALL (ROCCA)
Rawan G Faramand, Amy Zhang, Gregory W Roloff, et al.
Blood Advances
|
June 25, 2026
Improved Outcomes with TKI Maintenance Following Brexucabtagene Autoleucel in Philadelphia-chromosome ALL
Tamer Othman, Gregory W Roloff, Katharine Miller, et al.
Blood Cancer Journal
|
May 9, 2025
Outcomes of elderly patients with relapsed refractory multiple myeloma (RRMM) treated with teclistamab: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium
Oren Pasvolsky, Danai Dima, Lei Feng, et al.
Blood Advances
|
October 6, 2025
CAR HEMATOTOX independently predicts outcomes after CD19 CAR-T therapy for acute lymphoblastic leukemia
Yannis K Valtis, Chenyu Lin, David Nemirovsky, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 17, 2024
Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALL
Gregory W Roloff, Ibrahim Aldoss, Noam E Kopmar, et al.
Blood Advances
|
August 2, 2024
Impact of prior inotuzumab ozogamicin treatment on brexucabtagene autoleucel outcomes in adults with B-cell ALL
Ibrahim Aldoss, Gregory W Roloff, Rawan Faramand, et al.
Page
of 9